Avadel Pharmaceuticals plc

(NASDAQ:AVDL)

Latest On Avadel Pharmaceuticals plc (AVDL):

Date/Time Type Description Signal Details
2023-05-17 12:48 ESTNewsAvadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain BullishN/A
2023-05-04 21:04 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.48 misses by $0.10N/A
2023-05-03 19:46 ESTNewsAvadel Pharmaceuticals' Strategic Moves To Conquer The Narcolepsy Market (Rating Upgrade)N/A
2023-05-01 18:02 ESTNewsAvadel gains 12% as FDA issues final approval for sleep therapyN/A
2023-04-19 19:06 ESTNewsAvadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz LaunchN/A
2023-04-01 06:51 ESTNewsAvadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call TranscriptN/A
2023-03-30 23:36 ESTNewsAvadel Pharmaceuticals prices ADSs and Series B preferred shares offeringN/A
2023-03-30 23:36 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.44 misses by $0.17N/A
2023-03-29 23:23 ESTNewsAvadel Pharma enters into royalty agreement with RTW investments for up to $75MN/A
2023-03-22 22:21 ESTNewsAvadel stock rises on FDA nod to import sleep disorder drug Lumryz ahead of potential approvalN/A
2023-03-12 15:40 ESTNewsAvadel Pharmaceuticals: Real-World Data Supports Market Opportunity For LumryzN/A
2023-03-07 14:48 ESTNewsNavigating Avadel's Potential And Risks With LumryzN/A
2023-03-02 11:50 ESTNewsAvadel requests final FDA approval for Lumyrz in narcolepsyN/A
2023-03-02 11:50 ESTNewsSenators introduce legislation to eliminate drug company loophole that delays competitionN/A
2023-02-25 02:43 ESTNewsAvadel seeks full FDA approval for sleep therapy as Jazz loses patent appealN/A
2022-12-09 12:50 ESTNewsAvadel And Jazz: The Oxybate Wars - Duking It OutN/A
2022-12-07 06:29 ESTNewsAvadel: Lumryz Overhang Now Removed, Rate BuyN/A
2022-11-30 11:51 ESTNewsAvadel surges 13% as Jefferies upgrades on opportunity to dent Jazz's market shareN/A
2022-11-19 02:02 ESTNewsAvadel Pharmaceuticals jumps on patent win in dispute with Jazz Pharma (update)N/A
2022-11-11 23:25 ESTNewsAvadel at eight-month high as FTC comments raise prospects for lead drugN/A
2022-11-09 18:40 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.33 misses by $0.07N/A
2022-11-09 18:40 ESTNewsAvadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Call TranscriptN/A
2022-10-05 16:44 ESTNewsENPH, ATHX and AVDL among mid-day moversN/A
2022-09-06 20:37 ESTNewsAvadel's LUMRYZ: A Good Night's Sleep For Narcolepsy PatientsN/A
2022-09-05 11:33 ESTNewsAvadel Pharmaceuticals: Navigating Through The UncertaintyN/A
2022-09-01 00:30 ESTNewsAvadel Pharmaceuticals filed for 500M mixed shelf offeringN/A
2022-08-25 23:39 ESTNewsAvadel gains as judge delays hearing on patent dispute with Jazz PharmaN/A
2022-08-10 10:51 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 16:29 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$1.07 misses by $0.66N/A
2022-08-08 16:19 ESTNewsAvadel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-19 12:00 ESTNewsAvadel stock rises 8% as FDA grants tentative approval to its Jazz's sleep disorder drug rivalN/A
2022-06-30 04:47 ESTNewsAvadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023N/A
2022-06-17 06:54 ESTNewsAvadel: Further Delay, But Some Light At The End Of The TunnelN/A
2022-06-02 01:57 ESTNewsAvadel Pharmaceuticals reports insider transactions from Director, CEO & CFON/A
2022-05-27 14:51 ESTNewsAvadel spikes as Oppenheimer says selloff is overdoneN/A
2022-05-26 23:13 ESTNewsAvadel stock falls 26% as FDA cites patent issue in sleep disorder drug FT218 filing; expects tentative approval in 2023N/A
2022-05-26 23:13 ESTNewsJazz Pharmaceuticals benefitting from Avadel's daytime sleepiness drug delayN/A
2022-05-10 00:19 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.45 misses by $0.02N/A
2022-05-10 00:19 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-27 02:01 ESTNewsAvadel shares surge as company comments on recent trading activityN/A
2022-04-06 10:44 ESTNewsAvadel reports publication of data showing benefits of sleep disorder drug FT218N/A
2022-03-22 13:38 ESTNewsAvadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To SleepinessN/A
2022-03-18 08:57 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.38 beats by $0.03N/A
2022-03-18 08:57 ESTNewsAvadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-12 00:29 ESTNewsAvadel posts new efficacy and safety data for lead candidate in narcolepsyN/A
2021-11-09 01:43 ESTNewsAvadel Pharmaceuticals EPS beats by $0.01N/A
2021-11-09 01:43 ESTNewsAvadel records rising costs in Q3 amid plans to launch narcolepsy therapyN/A
2021-11-09 01:43 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-05 19:20 ESTNewsAvadel Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-01 13:34 ESTNewsAvadel Pharmaceuticals: I Am HoldingN/A

About Avadel Pharmaceuticals plc (AVDL):

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Quotes by TradingView

See Advanced Chart

General

  • Name Avadel Pharmaceuticals plc
  • Symbol AVDL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 32
  • Fiscal Year EndDecember
  • IPO Date1996-06-07
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.avadel.com
View More

Valuation

  • Trailing PE 71.85
  • Price/Sales (Trailing 12 Mt.) 11.79
  • Price/Book (Most Recent Quarter) 2.73
  • Enterprise Value Revenue 16.33
  • Enterprise Value EBITDA 37.99
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.32
  • Next Year EPS Estimate -$0.14
  • Next Quarter EPS Estimate -$0.25
  • Profit Margin 31%
  • Operating Margin -164%
  • Return on Assets -10%
  • Return on Equity 11%
  • Revenue 22.33 million
  • Earnings Per Share $0.13
  • Revenue Per Share $0.42
  • Gross Profit 16.59 million
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 546.06 million
  • EBITDA -38869000
  • PEG Ratio 0.07
  • Analyst Target Price $18.56
  • Book Value Per Share $2.78
View More

Share Statistics

  • Shares Outstanding 58.47 million
  • Shares Float 42.53 million
  • % Held by Insiders 589%
  • % Held by Institutions 56.94%
  • Shares Short 4.58 million
  • Shares Short Prior Month 3.77 million
  • Short Ratio 6.04
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.47
  • 52 Week High $12
  • 52 Week Low $4.83
  • 50 Day Moving Average 8.46
  • 200 Day Moving Average 6.8
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Avadel Pharmaceuticals plc (AVDL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Avadel Pharmaceuticals plc (AVDL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.19-$0.2830.91%
2020-09-302020-11-09$N/A-$0.20-$0.2518.37%
2020-06-302020-08-10$N/A$0.49-$0.10578.05%
2020-03-312020-05-11$12.24 million-$0.02-$0.2391.21%
2019-12-312020-03-12$11 million-$0.07-$0.2672.73%
2019-09-302019-11-12$14.23 million-$0.24-$0.2711.11%
2019-06-302019-08-09$17.55 million-$0.23-$0.2920.69%
2019-03-312019-05-08$16.44 million-$0.35-$0.4928.57%
2018-12-312019-03-15$20.92 million-$1.72-$2.3426.5%
2018-09-302018-11-05$19.83 million-$0.43-$0.36-21.13%
2018-06-302018-08-07$29.23 million-$0.09-$0.3271.88%
2018-03-312018-05-02$33.29 million-$0.32-$0.3713.51%
2017-12-312018-03-08$34.41 million-$0.24-$0.3735.14%
2017-09-302017-11-08$39.68 million$0.52-$0.023071.43%
2017-06-302017-08-08$45.21 million$0.68$0.09684.31%
2017-03-312017-05-09$52.51 million$0.59$0.11436.36%
2016-12-312017-03-07$43.09 million$0.11-$0.37129.73%
2016-09-302016-11-07$32.09 million-$0.54-$0.23-134.78%
2016-06-302016-08-08$38.86 million-$0.48$0.06-900%
2016-03-312016-05-09$36.22 million-$0.15$0.14-207.14%
2015-12-312016-03-10$44.57 million$1.75$0.091844.44%
2015-09-302015-11-12$47.31 million-$0.73$0.23-417.39%
2015-06-302015-07-30$48.6 million-$0.43$0.40-207.5%
2015-03-312015-05-15$32.53 million$0.27$0.31-12.9%
2014-12-312015-03-19$2.97 million-$0.69-$0.17-305.88%
2014-09-302014-10-31$2.91 million-$0.26-$0.12-116.67%
2014-06-302014-07-29$4.32 million-$0.13-$0.09-44.44%
2014-03-312014-05-12$4.58 million-$0.60-$0.15-300%
2013-12-312014-03-06$6.18 million$0.20-$0.16225%
2013-09-302013-10-31$5.58 million-$0.25-$0.20-25%
2013-06-302013-07-29$5.54 million-$1.21-$0.27-348.15%
2013-03-312013-05-07$5.14 million-$0.35-$0.33-6.06%
2012-12-312013-02-28$7.31 million$0.46-$0.19342.11%
2012-09-302012-11-05$5.4 million-$0.26-$0.19-36.84%
2012-06-302012-07-25$6.03 million$0.25-$0.08412.5%
2012-03-312012-05-07$7.36 million-$0.19-$0.07-171.43%
2011-12-312012-03-14$8.65 million-$0.08$0.10-180%
2011-09-302011-11-02$10.43 million$0.07-$0.09177.78%
2011-06-302011-07-25$6.75 million-$0.14-$0.09-55.56%
2011-03-312011-05-09$6.76 million-$0.20-$0.11-81.82%
2010-12-312011-03-03$13.45 million$0.11$0.05120%
2010-09-302010-11-04$8.04 million-$0.14
2010-06-302010-07-28$7.52 million-$0.18-$0.05-260%
2010-03-312010-05-05$8.09 million-$0.17-$0.13-30.77%
2009-12-312010-03-08$10.59 million-$0.23-$0.10-130%
2009-09-302009-11-16$9.9 million-$0.14-$0.09-55.56%
2009-06-302009-08-05$9.58 million-$0.15-$0.10-50%
2009-03-312009-05-11$12.05 million$0.05-$0.14135.71%
2008-12-312009-03-04$9.47 million-$0.11-$0.02-450%
2008-09-302008-11-03$9.14 million-$0.10-$0.1741.18%
2008-06-302008-08-06$9.15 million-$0.14-$0.2544%
2008-03-312008-05-13$10.87 million-$0.15-$0.2948.28%
2007-12-312008-03-03$10.56 million-$0.23-$0.3330.3%
2007-09-302007-10-30$9.02 million-$0.38-$0.417.32%
2007-06-302007-08-01$7.45 million-$0.57-$0.28-103.57%
2007-03-312007-05-07$9.63 million-$0.38-$0.33-15.15%
2006-12-312007-03-07$7.78 million-$0.25-$0.3732.43%
2006-09-302006-11-01$5.41 million-$0.43-$0.38-13.16%
2006-06-302006-07-31$4.74 million-$0.40-$0.33-21.21%
2006-03-312006-05-03$5.1 million-$0.41-$0.31-32.26%
2005-12-312006-03-07$6.26 million-$0.28-$0.3417.65%
2005-09-302005-10-26$3.09 million-$0.50-$0.37-35.14%
2005-06-302005-07-27$6.14 million-$0.41-$0.39-5.13%
2005-03-312005-05-05$8.11 million$0.01-$0.03133.33%
2004-12-312005-03-11$18.72 million$0.28$0.31-9.68%
2004-09-302004-10-28$13.35 million$0.12$0.119.09%
2004-06-302004-07-29$8.99 million-$0.07$0.07-200%
2004-03-312004-04-29$14.35 million$0.18$0.03500%
2003-12-312004-03-11$11.27 million$0.08$0.04100%
2003-09-302003-10-30$5.37 million-$0.11$0.05-320%
2003-06-302003-07-30$5 million-$0.10$0.02-600%
2003-03-312003-04-30$3.53 million-$0.10$0.03-433.33%
1998-12-311999-02-23-$0.12-$0.10-20%
1998-09-301998-10-27-$0.17-$0.13-30.77%
1998-06-301998-07-31-$0.22-$0.18-22.22%
1997-12-311998-03-17$0.00-$0.15100%
1997-06-301997-07-31-$0.22-$0.248.33%
1996-12-311997-03-26-$0.15-$0.1816.67%

Avadel Pharmaceuticals plc (AVDL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Avadel Pharmaceuticals plc (AVDL) Chart:

Avadel Pharmaceuticals plc (AVDL) News:

Below you will find a list of latest news for Avadel Pharmaceuticals plc (AVDL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Avadel Pharmaceuticals plc (AVDL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-212.50CALL0 0300.6TRUE00
2025-03-2152.8CALL0 3158.08TRUE00
2025-03-217.51.39CALL1 331189.02TRUE0.040.03
2025-03-21100.28CALL210 215279.43FALSE-0.07-0.2
2025-03-2112.50.13CALL0 112890.7FALSE00
2025-03-21150.05CALL0 2315120.84FALSE00
2025-03-2117.50.25CALL0 557144.69FALSE00
2025-03-21200.14CALL0 440233.51FALSE00
2025-03-2122.50.05CALL0 134253.51FALSE00
2025-03-21250.25CALL0 2234.83FALSE00
2025-03-21300CALL0 0299.6FALSE00
2025-03-212.50PUT0 0417.94FALSE00
2025-03-2150.1PUT0 63117.8FALSE00
2025-03-217.50.35PUT12 61083.22FALSE-0.03-0.08
2025-03-21101.78PUT1 98879.22TRUE-0.02-0.01
2025-03-2112.53.54PUT0 47380.52TRUE00
2025-03-21152.79PUT0 10128.57TRUE00
2025-03-2117.52.9PUT0 8154.26TRUE00
2025-03-21200PUT0 0153.59TRUE00
2025-03-2122.50PUT0 0222.58TRUE00
2025-03-212511.1PUT0 0261.51TRUE00
2025-03-21300PUT0 0238.36TRUE00
2025-04-172.50CALL0 0233.79TRUE00
2025-04-1750CALL0 099.18TRUE00
2025-04-177.50CALL0 024.05TRUE00
2025-04-17100CALL0 0116.32FALSE00
2025-04-1712.50CALL0 097.85FALSE00
2025-04-17150CALL0 0195.07FALSE00
2025-04-172.50PUT0 0485.98FALSE00
2025-04-1750PUT0 0246.61FALSE00
2025-04-177.50PUT0 078.73FALSE00
2025-04-17100PUT0 095.41TRUE00
2025-04-1712.50PUT0 093.09TRUE00
2025-04-17150PUT0 0186.84TRUE00
2025-06-202.55.65CALL0 6168.52TRUE00
2025-06-2053.7CALL0 1691.41TRUE00
2025-06-207.52.1CALL0 29179.2TRUE00
2025-06-20101.05CALL0 215678.36FALSE00
2025-06-2012.50.65CALL0 49476.08FALSE00
2025-06-20150.27CALL0 256677.91FALSE00
2025-06-2017.50.25CALL0 22574.35FALSE00
2025-06-20200.35CALL0 9180.07FALSE00
2025-06-2022.50.15CALL0 25123.74FALSE00
2025-06-20250.1CALL0 22132.27FALSE00
2025-06-20300CALL0 0146.46FALSE00
2025-06-202.50.15PUT0 5207FALSE00
2025-06-2050.3PUT0 780.53FALSE00
2025-06-207.50.91PUT0 24054.96FALSE00
2025-06-20102.38PUT1 24675.55TRUE2.380
2025-06-2012.54.34PUT0 15377.68TRUE00
2025-06-20154.8PUT0 4190.52TRUE00
2025-06-2017.50PUT0 0113.82TRUE00
2025-06-20200PUT0 0137.76TRUE00
2025-06-2022.50PUT0 0120.79TRUE00
2025-06-20250PUT0 0130.41TRUE00
2025-06-20300PUT0 0173.07TRUE00
2025-09-192.50CALL0 099.54TRUE00
2025-09-1950CALL0 074.15TRUE00
2025-09-197.52.74CALL0 1078.12TRUE00
2025-09-19101.45CALL0 12275.42FALSE00
2025-09-1912.51.05CALL0 3074.07FALSE00
2025-09-19150.55CALL0 6673.38FALSE00
2025-09-1917.50CALL0 074.83FALSE00
2025-09-192.50PUT0 0157.27FALSE00
2025-09-1950.4PUT0 175.51FALSE00
2025-09-197.51.15PUT0 4176.63FALSE00
2025-09-19102.5PUT0 5275.66TRUE00
2025-09-1912.50PUT0 075.32TRUE00
2025-09-19150PUT0 075.22TRUE00
2025-09-1917.50PUT0 064.4TRUE00
2026-01-162.50CALL0 093.78TRUE00
2026-01-1654CALL0 33365.94TRUE00
2026-01-167.53.4CALL0 28376.24TRUE00
2026-01-16101.9CALL11 840272.33FALSE-0.15-0.07
2026-01-1612.51.55CALL0 36673.48FALSE00
2026-01-16150.9CALL0 217273.21FALSE00
2026-01-1617.50.65CALL15 100071.89FALSE0.650
2026-01-16200.68CALL0 25972.07FALSE00
2026-01-1622.50.8CALL0 15373.37FALSE00
2026-01-16251.6CALL0 4072.92FALSE00
2026-01-16300.4CALL0 3767.04FALSE00
2026-01-16350.4CALL0 1109.89FALSE00
2026-01-162.50PUT0 0166.2FALSE00
2026-01-1650.4PUT0 1275.63FALSE00
2026-01-167.51.7PUT0 59673.78FALSE00
2026-01-16103.1PUT306 19972.17TRUE3.10
2026-01-1612.54.75PUT0 13771.49TRUE00
2026-01-16152.88PUT0 101171.81TRUE00
2026-01-1617.50PUT0 069.89TRUE00
2026-01-16200PUT0 0104.91TRUE00
2026-01-1622.50PUT0 071.57TRUE00
2026-01-16250PUT0 0120.29TRUE00
2026-01-16300PUT0 0132.53TRUE00
2026-01-16350PUT0 0148.18TRUE00
2027-01-152.50CALL0 087.26TRUE00
2027-01-1554.5CALL0 6879.24TRUE00
2027-01-157.54.09CALL0 15973.19TRUE00
2027-01-15103.3CALL0 24371.46FALSE00
2027-01-1512.51.95CALL0 2470.07FALSE00
2027-01-15152CALL10 5071.69FALSE20
2027-01-1517.55CALL0 569.03FALSE00
2027-01-15201.85CALL0 4568.57FALSE00
2027-01-1522.50.8CALL0 2067.98FALSE00
2027-01-15250.41CALL0 2168.87FALSE00
2027-01-15300CALL0 066.33FALSE00
2027-01-152.50PUT0 0125.53FALSE00
2027-01-1551.02PUT0 173.5FALSE00
2027-01-157.52.6PUT0 1168.57FALSE00
2027-01-15103.2PUT0 769.79TRUE00
2027-01-1512.54.6PUT0 368.97TRUE00
2027-01-15150PUT0 068.93TRUE00
2027-01-1517.56.9PUT0 168.11TRUE00
2027-01-15200PUT0 068.63TRUE00
2027-01-1522.50PUT0 068.37TRUE00
2027-01-15250PUT0 078.91TRUE00
2027-01-15300PUT0 097.03TRUE00

Latest AVDL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST300$2.245
Jun 13, 2022 7:59 PM EST360$2.245
Jun 13, 2022 7:59 PM EST140$2.245
Jun 13, 2022 7:59 PM EST634$2.245
Jun 13, 2022 7:59 PM EST2$2.25

Avadel Pharmaceuticals plc (AVDL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920080648/0001104659-20-080648-index.htm
2020-02-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1012477/000000000020001346/0000000000-20-001346-index.htm
2020-05-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1012477/000000000020004060/0000000000-20-004060-index.htm
2019-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000091068019000084/0000910680-19-000084-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000091957420001139/0000919574-20-001139-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247719000012/0001012477-19-000012-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000007/0001012477-20-000007-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000009/0001012477-20-000009-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000013/0001012477-20-000013-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919062085/0001104659-19-062085-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919066833/0001104659-19-066833-index.htm
2019-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919068803/0001104659-19-068803-index.htm
2019-12-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919069621/0001104659-19-069621-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919069622/0001104659-19-069622-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070110/0001104659-19-070110-index.htm
2019-12-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070118/0001104659-19-070118-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/0001104659-19-070213-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070217/0001104659-19-070217-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919071189/0001104659-19-071189-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919072792/0001104659-19-072792-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919073238/0001104659-19-073238-index.htm
2020-01-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920001912/0001104659-20-001912-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920003111/0001104659-20-003111-index.htm
2020-02-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1012477/000110465920010987/0001104659-20-010987-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020153/0001104659-20-020153-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020407/0001104659-20-020407-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020410/0001104659-20-020410-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920024077/0001104659-20-024077-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920032146/0001104659-20-032146-index.htm
2020-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920037990/0001104659-20-037990-index.htm
2020-04-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920047632/0001104659-20-047632-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920051182/0001104659-20-051182-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920051350/0001104659-20-051350-index.htm
2020-04-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920051827/0001104659-20-051827-index.htm
2020-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920053562/0001104659-20-053562-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920053569/0001104659-20-053569-index.htm
2020-05-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1012477/000110465920055587/0001104659-20-055587-index.htm
2020-05-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920058802/0001104659-20-058802-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920059095/0001104659-20-059095-index.htm
2020-06-16DEFR14ARevised definitive proxy soliciting materialshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920073527/0001104659-20-073527-index.htm
2020-06-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920076183/0001104659-20-076183-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920080648/0001104659-20-080648-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920082927/0001104659-20-082927-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920091513/0001104659-20-091513-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920092424/0001104659-20-092424-index.htm
2020-08-208-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920097315/0001104659-20-097315-index.htm
2020-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920100190/0001104659-20-100190-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920104616/0001104659-20-104616-index.htm
2019-12-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012565/0001179110-19-012565-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012567/0001179110-19-012567-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012826/0001179110-19-012826-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008889/0001179110-20-008889-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008890/0001179110-20-008890-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008891/0001179110-20-008891-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008892/0001179110-20-008892-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008893/0001179110-20-008893-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/0001179110-20-009023-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009024/0001179110-20-009024-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/0001179110-20-009084-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009086/0001179110-20-009086-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009461/0001179110-20-009461-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009462/0001179110-20-009462-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009709/0001179110-20-009709-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009877/0001179110-20-009877-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009897/0001179110-20-009897-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000119380520000194/0001193805-20-000194-index.htm
2020-03-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000121390020005412/0001213900-20-005412-index.htm
2019-12-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000149315219019859/0001493152-19-019859-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000149315220002411/0001493152-20-002411-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021621/0001567619-19-021621-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021625/0001567619-19-021625-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021875/0001567619-19-021875-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/0001567619-19-021885-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2020-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1012477/999999999520000371/9999999995-20-000371-index.htm
2020-05-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1012477/999999999520001129/9999999995-20-001129-index.htm

Avadel Pharmaceuticals plc (AVDL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Avadel Pharmaceuticals plc (AVDL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 589%
Institutional Ownership: 5694%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-13THOMAS S MCHUGHChief Financial OfficerBuy10,000.007.7877,814.0010,000.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009086/0001179110-20-009086-index.htm
2020-09-16Mark Anthony McCamishDirectorBuy118,602.005.73679,968.99118,602.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-09-17Mark Anthony McCamishDirectorBuy52,398.005.83305,249.79171,000.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-08-28THOMAS S MCHUGHChief Financial OfficerBuy7,500.006.7750,776.5017,500.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009462/0001179110-20-009462-index.htm
2020-09-18THOMAS S MCHUGHChief Financial OfficerBuy4,000.006.0024,000.0021,500.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009897/0001179110-20-009897-index.htm
2019-11-15Geoffrey Michael GlassDirectorBuy5,000.004.9924,950.0032,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2019-12-03Linda PalczukDirectorBuy7,500.005.9144,325.0035,400.00https://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/0001104659-19-070213-index.htm
2019-11-15Eric J EndeDirectorBuy10,000.004.9849,762.0037,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021875/0001567619-19-021875-index.htm
2020-08-14Linda PalczukDirectorBuy2,500.007.9419,849.7537,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/0001179110-20-009084-index.htm
2019-12-04Eric J EndeDirectorBuy10,000.005.9759,700.0047,900.00https://www.sec.gov/Archives/edgar/data/1012477/000110465919070217/0001104659-19-070217-index.htm
2019-11-18Geoffrey Michael GlassDirectorBuy15,000.004.9974,850.0047,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2020-08-12Geoffrey Michael GlassDirectorBuy6,500.007.7050,050.0054,400.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2019-12-12Sandra L HattenOfficerSell3,072.007.2322,210.5655,765.00https://www.sec.gov/Archives/edgar/data/1012477/000117911019012826/0001179110-19-012826-index.htm
2020-08-13Geoffrey Michael GlassDirectorBuy6,500.007.7650,440.0060,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2020-08-12Eric J EndeDirectorBuy15,000.007.76116,355.0062,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009024/0001179110-20-009024-index.htm
2020-08-13Eric J EndeDirectorBuy1,200.007.749,288.0064,100.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-08-28Geoffrey Michael GlassDirectorBuy4,800.006.7832,559.8465,700.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009461/0001179110-20-009461-index.htm
2020-08-13Eric J EndeDirectorBuy3,800.007.8029,640.0067,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-09-17Eric J EndeDirectorBuy17,000.005.7998,375.6084,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009877/0001179110-20-009877-index.htm
2019-11-15GREG J DIVISChief Executive OfficerBuy19,000.005.1397,470.0086,100.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/0001567619-19-021885-index.htm
2020-08-12Gregory J DivisChief Executive OfficerBuy13,000.007.78101,155.6099,100.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/0001179110-20-009023-index.htm